Apellis Pharmaceuticals Inc
NASDAQ:APLS
| Market Cap (Intraday) | 2.97B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $41.64 |
| 50-Day MA | $59.13 |
| 200-Day MA | $52.68 |
Apellis Pharmaceuticals Inc Stock, NASDAQ:APLS
100 Fifth Avenue, Suite A, Waltham, Massachusetts 02451
United States of America
Phone: +1.617.977.5700
Number of Employees: 374
Description
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.